<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Maternal anti-SSA antibodies are common, existing in up to 2 % of the general population </plain></SENT>
<SENT sid="1" pm="."><plain>Fetuses exposed to these antibodies are at risk for both cardiac and noncardiac complications </plain></SENT>
<SENT sid="2" pm="."><plain>The cardiac complications include <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, structural disease, and <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Although rare, the <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> associated with these antibodies is permanent and severe </plain></SENT>
<SENT sid="4" pm="."><plain>Current fetal echocardiographic screening tools are nonspecific </plain></SENT>
<SENT sid="5" pm="."><plain>The type and frequency of screening needed is controversial </plain></SENT>
<SENT sid="6" pm="."><plain>Although promising transplacental treatment strategies exist, prospective randomized studies are lacking </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="41879">Dexamethasone</z:chebi>, the medication used most frequently, imposes significant risks to both mother and fetus </plain></SENT>
<SENT sid="8" pm="."><plain>This report presents a discussion of the at-risk population, the spectrum of fetal <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> associated with maternal anti-SSA antibodies, the current fetal echocardiographic screening tools, the therapeutic options, and the management and delivery planning strategies </plain></SENT>
<SENT sid="9" pm="."><plain>With appropriate prenatal follow-up, assessment, and delivery planning, even high-risk fetuses can be delivered safely and managed effectively </plain></SENT>
</text></document>